UroGen (URGN) Q2 Revenue Rises 11%

UroGen Pharma (NASDAQ:URGN), a uro-oncology company, reported second quarter 2025 earnings on August 7, 2025. The highlight was the FDA approval and launch of ZUSDURI (mitomycin) for recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, a major expansion beyond its existing JELMYTO (mitomycin) product. Net product revenue (GAAP) reached $24.2 million, beating the Street’s $23.1 million GAAP target. However, the company posted a net loss per share of ($1.05) under GAAP, mainly due to higher selling, general and administrative expenses as the ZUSDURI commercialization effort scaled up. The quarter marked strong commercial execution and pipeline progress, though near-term profitability and cash flow remain pressured by elevated investment in growth initiatives and a rapid cash burn rate. Source: Analyst estimates provided by FactSet. Management expectations based on management's guidance, as provided in Q1 2025 earnings report. UroGen Pharma develops and commercializes therapies for urologic cancers using its proprietary RTGel technology. RTGel is a hydrogel that transforms from liquid to gel at body temperature, enabling long-lasting delivery of drugs directly to the urinary tract. With JELMYTO (mitomycin) already approved for treatment of low-grade upper tract urothelial carcinoma (a rare, non-invasive urinary tract cancer) and now ZUSDURI for bladder cancer, the company’s focus is expanding to address larger patient populations.Continue readingWeiter zum vollständigen Artikel bei MotleyFool Weiter zum vollständigen Artikel bei MotleyFool